The biochemistry of Heart Attacks and the Challenges of Discovering New Medicines
Carl Sparrow, Ph.D.
Managing Partner, Sparrow Consulting, LLC
11:00 AM, Monday, June 11
Khorana Auditorium, HFD Biochemistry Laboratories
Lunch round table in room 179 with trainees* following the seminar
Carl Sparrow received a Bachelor of Science in Chemistry from Brown University in 1979, and a PhD in biochemistry from the University of Wisconsin, Madison, in 1985, in the laboratory of Christian Raetz on phospholipid metabolism in E. coli. He switched to mammalian lipid metabolism as a postdoctoral fellow in the laboratory of Daniel Steinberg at UC San Diego.
Carl then worked Merck Research Laboratories in Rahway New Jersey for 24 years. He worked on the identification and development of Anacetrapib, an inhibitor of the cholesteryl ester transfer protein. After 19 years in Basic Research at Merck, and rising through the ranks to the position of Director, Lipid Biochemistry, Carl moved within the Merck organization to Regulatory Affairs. In that position, he was the liaison between Merck and regulatory agencies such as the FDA for a number of Merck products and investigational drugs. Since leaving Merck in 2013, Carl has been working as an independent scientific consultant, mostly advising small biotech firms on interactions with FDA.
Carl will discuss the development of Anacetrapib and more generally, the landscape for drug discovery in the pharmaceutical industry.
*Graduate students & post-docs: please RSVP to Crystal Peterson if you wish to participate in the lunch with Carl Sparrow: email@example.com